Top Markets
Coin of the day
20/20 Biolabs Inc. 20/20 Biolabs Inc.

20/20 Biolabs Inc.

AIDX
Rang in Aktien #33871
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company... 20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
Aktienkurs
$0.5475
Zuletzt synchronisiert: 2026-08-14
Marktkapitalisierung
$6.71M
Veränderung (1 Tag)
5.57%
Veränderung (1 Jahr)
-
Land
US
Handel 20/20 Biolabs Inc. (AIDX)

Kategorie

EPS für 20/20 Biolabs Inc. (AIDX)
EPS zum 2026 TTM: 0
Laut den aktuellen Finanzberichten und dem Aktienkurs von 20/20 Biolabs Inc. beträgt das aktuelle EPS des Unternehmens (TTM) 0. Am Ende des Jahres 2026 betrug das EPS 0 gleich wie dem EPS von 2026, das 0 betrug.
EPS-Verlauf von 20/20 Biolabs Inc. von 2026 bis 2026
EPS am Ende jedes Jahres
Jahr EPS ändert
Nicht genügend Daten für die angegebenen Daten.
EPS für ähnliche Unternehmen oder Wettbewerber